Combining TGF-β inhibition and angiotensin II blockade results in enhanced antifibrotic effect

Kidney International

Volumn 66, Issue 5, 2004, Pages 1774-1784

  Yu, Ling ^b   Border, Wayne A ^b   Anderson, Ian ^b   McCourt, Matthew ^b   Huang, Yufeng ^b   Noble, Nancy A ^a  

^a Fibrosis Research Laboratory   (United States)

^b NONE

Author keywords

Angiotensin II; Fibrosis; Kidney; Neutralizing antibody; TGF

Indexed keywords

ANGIOTENSIN; ANTIFIBROTIC AGENT; COLLAGEN TYPE 1; DRINKING WATER; ENALAPRIL; FIBRONECTIN; MESSENGER RNA; MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMAD1 PROTEIN; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; DOSE CALCULATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; ENZYME INHIBITION; GLOMERULONEPHRITIS; KIDNEY FIBROSIS; MEDICAL ASSESSMENT; NONHUMAN; PERIODIC ACID SCHIFF STAIN; PRIORITY JOURNAL; ANIMAL; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; FIBROSIS; IMMUNOLOGY; KIDNEY; MALE; METABOLISM; MOUSE; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENALAPRIL; FIBROSIS; GLOMERULONEPHRITIS; KIDNEY; MALE; MICE; RATS; RATS, SPRAGUE-DAWLEY; TRANSFORMING GROWTH FACTOR BETA;

EID: 15844402989     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00901.x     Document Type: Article

References (59)

1. SCHENA FP: Epidemiology of end-stage renal disease: International comparisons of renal replacement therapy. Kidney Int 57:39-45, 2000
2. KLAHR S, SCHREINER G, ICHIKAWA I: The progression of renal disease. N Engl J Med 318:1657-1666, 1988
3. BORDER WA, NOBLE NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 331:1286-1292, 1994
4. TAAL MW, BRENNER BM: Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int 57:1803-1817, 2000
5. LEWIS EJ, HUNSICKER LG, BAIN RP, et al: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
6. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group. Diabetologia 39:587-593, 1996
7. YUSUF S, SLEIGHT P, POGUE J, et al: Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000
8. MASCHIO G, ALBERTI D, JANIN G, et al: Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334:939-945, 1996
9. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349:1857-1863, 1997
10. RAVID M, SAVIN H, JUTRIN I, et al: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:577-581, 1993
11. LEWIS EJ, HUNSICKER LG, CLARKE WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
12. BRENNER BM, COOPER ME, DE ZEEUW D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
13. PETERS H, BORDER WA, NOBLE NA: Targeting TGF-beta overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 54:1570-1580, 1998
14. BORDER WA, OKUDA S, LANGUINO LR, et al: Transforming growth factor-beta regulates production of proteoglycans by mesangial cells. Kidney Int 37:689-695, 1990
15. OKUDA S, LANGUINO LR, RUOSLAHTI E, et al: Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis. J Clin Invest 86:453-462, 1990
16. BORDER WA, OKUDA S, LANGUINO LR, et al: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 346:371-374, 1990
17. ISAKA Y, TSUJIE M, ANDO Y, et al: Transforming growth factor-beta 1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction. Kidney Int 58:1885-1892, 2000
18. HAN DC, HOFFMAN BB, HONG SW, et al: Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Am J Physiol Renal Physiol 278:F628-634, 2000
19. ISAKA Y, AKAGI Y, ANDO Y, et al: Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 55:465-475, 1999
20. VILCHIS-LANDEROS MM, MONTIEL JL, MENDOZA V, et al: Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent. Biochem J 355:215-222, 2001
21. BORDER WA, NOBLE NA, YAMAMOTO T, et al: Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 360:361-364, 1992
22. ISAKA Y, BREES DK, IKEGAYA K, et al: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med 2:418-423, 1996
23. BOTTINGER EP, FACTOR VM, TSANG ML, et al: The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. Proc Natl Acad Sci USA 93:5877-5882, 1996
24. KANAMARU Y, NAKAO A, MAMURA M, et al: Blockade of TGF-beta signaling in T cells prevents the development of experimental glomerulonephritis. J Immunol 166:2818-2823, 2001
25. YEVDOKIMOVA N, WAHAB NA, MASON RM: Thrombospondin-1 is the key activator of TGF-beta1 in human mesangial cells exposed to high glucose. J Am Soc Nephrol 12:703-712, 2001
26. SHARMA K, JIN Y, GUO J, et al: Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45:522-530, 1996
27. ZIYADEH FN, HOFFMAN BB, HAN DC, et al: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015-8020, 2000
28. MIYAJIMA A, CHEN J, LAWRENCE C, et al: Antibody to transforming growth factor-beta ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int 58:2301-2313, 2000
29. HILL C, FLYVBJERG A, RASCH R, et al: Transforming growth factor-beta2 antibody attenuates fibrosis in the experimental diabetic rat kidney. J Endocrinol 170:647-651, 2001
30. DAHLY AJ, HOAGLAND KM, FLASCH AK, et al: Antihypertensive effects of chronic anti-TGF-beta antibody therapy in Dahl S rats. Am J Physiol Regul Integr Comp Physiol 283:R757-767, 2002
31. GIRI SN, HYDE DM, HOLLINGER MA: Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 48:959-966, 1993
32. WOLF YG, RASMUSSEN LM, RUOSLAHTI E: Antibodies against transforming growth factor-β1 suppress intimal hyperplasia in a rat model. J Clin Invest 93:1172-1178, 1994
33. SHAH M, FOREMAN DM, FERGUSON MWJ: Control of scarring in adult wounds by neutralising antibody to transforming growth factor β. Lancet 339:213-214, 1992
34. YAMAMOTO T, TAKAGAWA S, KATAYAMA I, et al: Anti-sclerotic effect of transforming growth factor-beta antibody in a mouse model of bleomycin-induced scleroderma. Clin Immunol 92:6-13, 1999
35. BOWES LE, JIMENEZ MC, HIESTER ED, et al: Collagen fiber orientation as quantified by small angle light scattering in wounds treated with transforming growth factor-beta2 and its neutalizing antibody. Wound Repair Regen 7:179-186, 1999
36. BAGCHUS WM, HOEDEMAEKER PJ, ROZING J, et al: Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies. A sequential histological and ultrastructural study in the rat. Lab Invest 55:680-687, 1986
37. RENNARD SI, BERG R, MARTIN GR, et al: Enzyme-linked immunoassay (ELISA) for connective tissue components. Anal Biochem 104:205-214, 1980
38. YAMAMOTO T, NOBLE NA, COHEN AH, et al: Expression of transforming growth factor-β isoforms in human glomerular diseases. Kidney Int 49:461-469, 1996
39. GENOVESE C, ROWE D, KREAM B: Construction of DNA sequences complementary to rat alpha 1 and alpha 2 collagen mRNA and their use in studying the regulation of type I collagen synthesis by 1,25-dihydroxyvitamin D. Biochem 23:6210-6216, 1984
40. SCHWARZBAUER JE, TAMKUN JW, LEMISCHKA IR, et al: Three different fibronectin mRNAs arise by alternative splicing within the coding region. Cell 35:421-431, 1983
41. ZEHEB R, GELEHRTER TD: Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1. Gene 73:459-468, 1988
42. DERYNCK R, JARRETT JA, CHEN EY, et al: The murine transforming growth factor-beta precursor. J Biol Chem 261:4377-4379, 1986
43. WESTERHUIS R, VAN STRAATEN SC, VAN DIXHOORN MG, et al: Distinctive roles of neutrophils and monocytes in anti-thy-1 nephritis. Am J Path 156:303-310, 2000
44. PETERS H, BORDER WA, NOBLE NA: Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis. Kidney Int 57:992-1001, 2000
45. PETERS H, BORDER WA, NOBLE NA: Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis. Kidney Intl 57:1493-1501, 2000
46. FERN RJ, YESKO CM, THORNHILL BA, et al: Reduced angiotensinogen expression attenuates renal interstitial fibrosis in obstructive nephropathy in mice. J Clin Invest 103:39-46, 1999
47. BENIGNI A, CORNA D, MAFFI R, et al: Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Kidney Int 54:353-359, 1998
48. REMUZZI G, ZOJA C, GAGLIARDINI E, et al: Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 10:1542-1549, 1999
49. AMANN K, SIMONAVICIENE A, MEDWEDEWA T, et al: Blood pressure-independent additive effects of pharmacologic blockade of the renin-angiotensin and endothelin systems on progression in a low-renin model of renal damage. J Am Soc Nephrol 12:2572-2584, 2001
50. BENIGNI A, ZOJA C, CORNA D, et al: Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 14:1816-1824, 2003
51. ISLAM M, BURKE JF, MCGOWAN TA, et al: Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction. Kidney Int 59:498-506, 2001
52. KAGAMI S, BORDER WA, MILLER DE, et al: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 93:2431-2437, 1994
53. FUKUDA N, HU WY, KUBO A, et al: Abnormal regulation of transforming growth factor-beta receptors on vascular smooth muscle cells from spontaneously hypertensive rats by angiotensin II. Hypertens 31:672-677, 1998
54. SIEGERT A, RITZ E, ORTH S, et al: Differential regulation of transforming growth factor receptors by angiotensin II and transforming growth factor-beta1 in vascular smooth muscle. J Mol Med 77:437-445, 1999
55. WOLF G, ZIYADEH FN, STAHL RA: Angiotensin II stimulates expression of transforming growth factor beta receptor type II in cultured mouse proximal tubular cells. J Mol Med 77:556-564, 1999
56. LETTERIO JJ, ROBERTS AB: Regulation of immune responses by TGF-beta. Annu Rev Immunol 16:137-161, 1998
57. PAWLUCZYK IZ, HARRIS KP: Transforming growth factor-beta suppresses macrophage-induced mesangial cell fibronectin expression. Kidney Int 60:533-542, 2001
58. SUTO TS, FINE LG, SHIMIZU F, et al: In vivo transfer of engineered macrophages into the glomerulus: Endogenous TGF-beta-mediated defense against macrophage-induced glomerular cell activation. J Immunol 159:2476-2483, 1997
59. LING H, LI X, JHA S, et al: Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: Morphologic improvement associated with functional preservation. J Am Soc Nephrol 14:377-388, 2003